Clinical Research Programs
Review clinical research programs by faculty:
- Dennis Hallahan, M.D.
- Jeffrey
Bradley, M.D
- Joseph O Deasy, Ph.D.
- Issam M. El Naqa Ph.D.
- Perry Grigsby, M.D.
- David Mansur, M.D.
- Jeff
Michalski, M.D.
- Robert
Myerson, Ph.D., M.D.
- Wade
Thorstad, M.D.
- Xiaowei Wang Ph.D.
- Imran Zoberi, M.D.
Dennis Hallahan, M.D.
Neurobiology and Signal Transduction
The Hallahan laboratory studies the mechanisms of cell death in normal tissues during cancer therapy. In particular, we have found that a signal transduction pathway required for radiation induced apoptosis in normal tissues involves glycogen synthase kinase 3beta. GSK-3beta regulates the apoptosis machinery within normal tissues. Cancer cells do not require GSK-3beta or apoptotic machinery to respond to cancer therapy. In contrast, injuries in normal tissues such as the brain and intestine require GSK-3 signaling. We have found that inhibitors of GSK-3beta prevent injury in normal tissues. These inhibitors prevent injury to the brain and improve neurocognitive function and reduce injury in the intestine of animal models. Presently, we are studying the mechanisms by which GSK-3 inhibition prevents program cell death in normal tissues. Studies involve the epigenetic response to GSK-3 inhibitors. We identify transcription factors and apoptotic machinery that are activated during cancer therapy but inhibited during GSK-3 blockade.
Developmental Therapeutics in Cancer
The Hallahan laboratory has identified several peptides and over a dozen monoclonal antibodies that bind to cancer following treatment with ionizing radiation. Using this strategy, drug delivery can be targeted specifically to cancer and guided by use of a beam of radiation therapy. These targeting ligands have been conjugated to the drug delivery systems, including liposomes and nanoparticles to improve he specificity of drug delivery of cancer.
The Hallahan laboratory collaborates extensively with pharmaceutical companies to identify radiation sensitizing and radiation protecting drugs. Pre-clinical efficacy studies were conducted in mouse models of human cancer.
Immunotherapy
The Hallahan laboratory also characterizes the immunological response of antibodies targeted by radiation. These monoclonal antibodies bind to radiation inducible neo-antigens. These antibodies can activate immune response. In addition, therapeutic agents are conjugated to the antibodies to provide cancer specific drug delivery. Identification of radiation inducible neo-antigens involves the co-precipitation of antigens from cancer by use of monoclonal antibodies. Antigens are then identified by use of proteomic technology. Humanization of these mouse monoclonal antibodies will be performed with the goal of bringing antibodies into clinical trials. Optimization and humanization strategies for antibodies is a primary goal of the laboratory.
[back to top]
Jeffrey
Bradley, M.D
| Title |
PIName |
ProtocolNumber |
| IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients |
Bradley, Jeffrey D |
06-1070 |
| A Phase I/II Trial of Stereotactic Body Radiation therapy (SBRT) Dose Escalation in the Treatment of Patients with Inoperable Stage I/II Non-Small Cell Lung Cancer Arising within the Zone of the Proximal Bronchial Tree |
Bradley, Jeffrey D |
06-0691 |
| Retrospective Review of Stereotactic Body Radiation Therapy (SBRT) for Cancerous Lesions in the Lung |
Bradley, Jeffrey D |
07-0315 |
| Stereotactic Radiosurgery (SRS) for One or Two Localized Spine Metastases |
Bradley, Jeffrey D |
07-0658 |
| CIRB RTOG 0617 - A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patient with Stage IIIA/IIIB Non-Small Cell Lung Cancer |
Bradley, Jeffrey D |
RTOG 0617 |
| A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer |
Bradley, Jeffrey D |
RTOG 0618 |
[back to top]
Joseph O Deasy, Ph.D.
| Title |
PIName |
ProtocolNumber |
| Outcomes Analysis for Brain Radiation Treatments |
Deasy, Joseph O |
05-0531 |
[back to top]
Issam M. El Naqa Ph.D.
| Title |
PIName |
ProtocolNumber |
| Ancillary Study for Evaluating Tissue-Based Biomarker Predictors of Response to Radiation Therapy in Patients with Non-Small Cell Lung Cancer |
El Naqa, Issam M |
08-0800 |
| Retrospective analysis of NSCLC patients outcomes based on FDG-PET characteristics |
El Naqa, Issam M |
08-0347 |
| Combined Physical and Biological Markers for Statistical Modeling of Radiotherapy Outcomes in Non-Small Cell Lung Cancer |
El Naqa, Issam M |
06-1099 |
| Ancillary Study Evaluating FLT-PET as a Predictor of Cellular Proliferation for Response to Radiation Therapy and in Patients with Non Small Cell Lung Cancer |
El Naqa, Issam M |
08-1171 |
[back to top]
Perry Grigsby, M.D.
| Title |
PIName |
ProtocolNumber |
| Molecular Markers Associated with Poor Prognosis in Cervical Cancer |
Grigsby, Perry W |
05-0294 |
| Treatment Outcomes after Eye Plaque Brachytherapy for Patients with Uveal Melanoma |
Grigsby, Perry W |
05-1070 |
| Differential Gene Expression Profiles in Cervical Cancer |
Grigsby, Perry W |
07-0958 |
| Prospective Data Collection Study of Dosimetry Information for Patients Being Treated with Standard Vaginal Brachytherapy for Gynecologic Cancer |
Grigsby, Perry W |
08-0935 |
| Dosimetry and Toxicity of IMRT Radiation for Gynecologic Cancer |
Grigsby, Perry W |
06-0840 |
| Microarray and Molecular Marker Analysis in Cervical Cancer |
Grigsby, Perry W |
06-1108 |
| Pelvic IMRT with Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients |
Grigsby, Perry W |
06-0297 |
| Familial Well-Differentiated Thyroid Cancer |
Grigsby, Perry W |
06-0158 |
| Molecular Markers Associated with Poor Prognosis in Hypoxic Colo-Rectal Cancers |
Grigsby, Perry W |
05-0271 |
| FDG-PET in Anal Cancer |
Grigsby, Perry W |
05-0709 |
| Pelvic IMRT with Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients |
Grigsby, Perry W |
05-0977 |
| Functionality of DNA Repair Pathways in Tumor Tissue Correlated with Clinical Outcomes |
Grigsby, Perry W |
07-0178 |
| Roche Elecsys® Thyroglobulin |
Grigsby, Perry W |
07-0572 |
| A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High Risk, clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy |
Grigsby, Perry W |
RTOG 0622 |
| Randomized Phase II Study of Zoledronic Acid vs Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer |
Grigsby, Perry W |
09-0811 |
[back to top]
David Mansur, M.D.
| Title |
PIName |
ProtocolNumber |
| Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post-Irradiation Temozolomide for Primary Central Nervous System Lymphoma |
Mansur, David B |
RTOG 0227 |
| Retrospective Chart Review of Outcome Following Radiation Therapy for Low Grade Gliomas |
Mansur, David B |
08-1355 |
| Prospective Data Collection, Image Analysis, and Comparison Planning for Uveal Melanoma Patients Receiving Standard Treatment with l-125 Episcleral Brachytherapy |
Mansur, David B |
08-1247 |
[back to top]
Jeff
Michalski, M.D.
| Title |
PIName |
ProtocolNumber |
| Quality Research in Radiation Oncology 2007 Process Survey |
Michalski, Jeff M |
08-0923 |
| Advanced Technology QA Center |
Michalski, Jeff M |
99-0378 |
| A Phase III Randomized Study of High Dose 3D-CRT versus Standard Dose 3D-CRT in Patients Treated for Localized Prostate Cancer (8/21/2008 - ENROLLING ONLY EXISTING PATIENTS INTO THE SUBSTUDY) |
Michalski, Jeff M |
RTOG P-0126 |
| A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma |
Michalski, Jeff M |
RTOG 0232 |
| CA - 104342 Dose Volume Analyses of Late Rectal and Bladder Cancer Toxicity |
Michalski, Jeff M |
05-1018 |
| A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer CIRB |
Michalski, Jeff M |
RTOG 0415 |
| Investigating Markers of Radiation Outcome in Patients with Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study |
Michalski, Jeff M |
RTOG 0612 |
| A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy |
Michalski, Jeff M |
RTOG 0534 |
| Pilot To Reduce Missing RTOG Quality Of Life Data Via Electronic Web-Based Form Collection: A Companion Study For RTOG 0415 (A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT In Patients With Favorable-Risk Prostate Cancer) |
Michalski, Jeff M |
RTOG 0828 |
| Sub-Study: 3D/OG 9406: A Phase I/II Dose Escalation Study Using Three Dimensional Conformal Radiation Therapy for Adenocarcinoma for the Prostate (existing patients only) |
Michalski, Jeff M |
RTOG 94-06 |
| RTOG 0621 Adjuvant 3DCRT/IMRT in Cominbation with Androgen Suppression and Docetaxel for High Risk Porstate Cancer Patients Post-Prostatectomy: a Phase II Trial |
Michalski, Jeff M |
RTOG 0621 |
[back to top]
Robert
Myerson, Ph.D., M.D.
| Title |
PIName |
ProtocolNumber |
| A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination with Capecitabine and Oxaliplatin for Patient with Locally Advanced Rectal Cancer |
Myerson, Robert J |
RTOG 0822 |
[back to top]
Wade
Thorstad, M.D.
| Title |
PIName |
ProtocolNumber |
| Functional and Quality of Life Assessment in Head and Neck Cancer Patients Status Post Radiation Therapy |
Thorstad, Wade L |
07-0270 |
| Phase II Trial Evaluating Elimination of Radiation Therapy to Pathological N0 Neck(s) with Intensity Modulated Postoperative Radiation Therapy |
Thorstad, Wade L |
07-0142 |
| IMRT Treatment Outcome/Pattern of Failure Analysis |
Thorstad, Wade L |
04-0454 |
| Retrospective FDG-PET/CT for Radiotherapy Treatment Planning Head and Neck Cancer |
Thorstad, Wade L |
05-0745 |
| Retrospective Review of Outcome in Cervical Metastases from Unknown Primaries |
Thorstad, Wade L |
08-0944 |
| Image Bank Protocol for Patients with Head and Neck Cancer |
Thorstad, Wade L |
08-0724 |
| Investigating Predictive Models for Determining Head and Neck Cancer Response to Radiotherapy: An Image Bank Protocol Ancillary Study |
Thorstad, Wade L |
08-1322 |
| A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck |
Thorstad, Wade L |
RTOG 0619 |
[back to top]
Xiaowei Wang Ph.D.
| Title |
PIName |
ProtocolNumber |
| Meta Analysis of High-Throughput Data from Public Databases for Human Cancer Studies |
Wang, Xiaowei |
08-1102 |
[back to top]
Imran Zoberi, M.D.
| Title |
PIName |
ProtocolNumber |
| Retrospective Review of Factors Affecting the Quality of Breast Brachytherapy |
Zoberi, Imran |
08-0389 |
| Stereotactic Radiosurgery in Patients with Brain Metastasis from Breast Cancer |
Zoberi, Imran |
04-0380 |
| Partial Breast Irradiation (PBI) for Selected Patients with Early Breast Cancer: A Phase I Feasibility Study |
Zoberi, Imran |
05-1053 |
| Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study |
Zoberi, Imran |
07-1077 |
